Apotex Gains Health Canada Nod for Osteoporosis Biosimilar DENOZA
Event summary
- Health Canada approved Apotex's DENOZA™, a biosimilar to Prolia®, for osteoporosis treatment on April 7, 2026.
- DENOZA is authorized for postmenopausal women and men at high risk for fracture, with additional indications matching the reference biologic.
- The product will be available in a prefilled syringe format.
- Apotex positions DENOZA as expanding treatment options for over 2.3 million Canadians with osteoporosis.
The big picture
Apotex's approval of DENOZA strengthens its position in the biosimilars market, addressing a significant public health issue in Canada. The introduction of biosimilars like DENOZA is part of a broader trend toward expanding affordable treatment options, particularly in chronic conditions like osteoporosis. This move aligns with Apotex's strategy of improving access to healthcare while contributing to a sustainable healthcare system.
What we're watching
- Market Penetration
- How DENOZA will compete against Prolia® in the Canadian osteoporosis market.
- Pricing Strategy
- Whether Apotex can sustain competitive pricing while maintaining profitability.
- Regulatory Expansion
- The pace at which Apotex seeks approvals for DENOZA in other global markets.
Related topics